News|Articles|November 17, 2026

GLP-1 users with prediabetes had fewer heart events than metformin users

Listen
0:00 / 0:00

Key Takeaways

  • A TriNetX EHR study matched 128,846 GLP-1 initiators to 128,846 metformin initiators with obesity and prediabetes, excluding baseline ASCVD, HF, stroke, and AF.
  • GLP-1 therapy increased normoglycemia reversion (37.3% vs 29.3%; HR 1.53) and reduced diabetes progression (25.1% vs 37.0%; HR 0.69).
SHOW MORE

In more than 256,000 adults with prediabetes and obesity, GLP-1s were linked to better blood sugar and heart outcomes than metformin, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2026.

Adults with prediabetes and obesity who started a GLP-1 drug had lower rates of heart failure, stroke, heart attack and death than those who started metformin, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2026, held Nov. 6-9 in Chicago. These folks were also more likely to return to normal blood sugar and less likely to develop diabetes.

None of the patients had ischemic heart disease, heart failure, stroke or atrial fibrillation when they started treatment. According to researchers, the void of these conditions at the start puts the focus on preventing a first cardiovascular event rather than a repeat one.

Findings come from a look back at health records, not a randomized trial. Researchers at Mayo Clinic in Arizona, including lead author and research fellow in cardiology, Vinicius de Sousa Barzon Serra, said prospective trials are still needed to confirm cause and effect.

Heart disease is the leading cause of death in the U.S., according to the CDC. Prediabetes, which affects about 40% of U.S. adults according to the researchers, raises the risk of both cardiovascular disease and type 2 diabetes, especially in people with obesity. Metformin, a low-cost generic, has long been used to help prevent diabetes in this group, though it isn't FDA-approved for that use. GLP-1 drugs have shown metabolic benefits beyond those of metformin. But head-to-head data on blood sugar and heart outcomes in prediabetes have been limited, the authors wrote.

GLP-1 users more often returned to normal blood sugar

Researchers used electronic health records from 104 healthcare organizations in the TriNetX network, covering 2010 through 2023. They included adults with prediabetes and obesity who started metformin or one of four GLP-1-based drugs: Ozempic or Wegovy (semaglutide), Mounjaro or Zepbound (tirzepatide), Victoza or Saxenda (liraglutide) and Trulicity (dulaglutide). Tirzepatide also acts on a second hormone receptor, GIP.

Exact brand names used were not identified in the abstract.

Anyone with diabetes, stroke, heart failure, atrial fibrillation or ischemic heart disease before starting treatment was excluded. Researchers then matched the two groups on demographics, other health conditions, medications and lab values to make them as comparable as possible.

The final analysis included more than 256,000 patients, with 128,846 in each group. Average age was 52.4, and 76.1% were women, and the average body mass index (BMI) was 39.5 in the GLP-1 group and 38.5 in the metformin group.

During follow-up, 37.3% of GLP-1 users returned to normal blood sugar, compared with 29.3% of metformin users. That translated to a 53% higher likelihood of reversion (hazard ratio [HR] 1.53).

Fewer GLP-1 users progressed to diabetes: 25.1%, compared with 37.0% of metformin users. That's a 31% lower risk (HR 0.69).

Fewer deaths and heart events

GLP-1 therapy was also associated with a 41% lower risk of death from any cause (HR 0.59). Risk was lower for acute heart failure (HR 0.74), ischemic stroke (HR 0.80), heart attack (HR 0.84), cardiac arrest (HR 0.58) and atrial fibrillation (HR 0.92). Risk of ventricular tachycardia, a fast and potentially dangerous heart rhythm, didn't differ between the groups.

That's a different population from the one in SELECT, the trial that led the FDA in March 2024 to approve Wegovy to lower the risk of heart attack, stroke and cardiovascular death in adults with established heart disease and overweight or obesity. In SELECT, which enrolled 17,604 patients without diabetes, Wegovy cut those events by 20% compared with placebo.

The new study has limits. Because it was observational, the groups may have differed in ways matching couldn't capture, such as access to care or insurance coverage. The abstract also doesn't report how long patients stayed on treatment or results for individual drugs.

Cost and coverage questions for plans

For payers, the price gap between the two options is wide. Metformin is an inexpensive generic, while GLP-1 drugs are brand-name products that cost far more.

Coverage for obesity also remains limited, especially in Medicare. Under the Medicare GLP-1 Bridge pilot, which runs from July 1, 2026, through Dec. 31, 2027, eligible Part D enrollees can get Wegovy, Zepbound KwikPens and Foundayo (orforglipron) for weight loss for a $50 monthly copay with prior authorization, according to CMS.

The authors wrote that their findings support a growing role for GLP-1 drugs in preventing diabetes and lowering cardiovascular risk. Randomized trials are needed to confirm causality, they added.


Related to this article